A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1b, multicenter, 2-part study of ALRN-6924 for the prevention of
chemotherapy-induced side effects.
Part 1 SCLC is an open-label, multicenter study of ALRN-6924 for the prevention of
chemotherapy-induced side effects in patients with p53-mutated ED SCLC undergoing 2nd-line
treatment with topotecan. (Part 1 has completed enrollment).
Part 2 NSCLC is a randomized, double-blind, placebo-controlled, multicenter study of
ALRN-6924 for the prevention of chemotherapy-induced side effects in patients with
p53-mutated advanced NSCLC of adenocarcinoma histology receiving 1st-line treatment with
carboplatin plus pemetrexed with or without immunotherapy.